
Rodney JY Ho
· Professor; Exec. Dir.—WE-REACH*; Dir.—TLC- ART†; Affiliate Member of Fred Hutch; Affiliate Faculty, CFAR^; Member of ITHS‡University of Washington · Pharmacology
Active 1985–2025
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Rodney JY Ho is a professor and presidential entrepreneurial fellow at the University of Washington, with appointments at the Fred Hutchinson Cancer Research Center. He is the founding Executive Director of the Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH), a NIH-designated National Hub. Dr. Ho's research focuses on bio-nanotechnology and bio-pharmaceuticals, enabling the transformation of basic biomedical discoveries into therapeutics. His work emphasizes innovations in targeted and drug combination synchronous delivery, with a particular focus on treatments for cancer and infectious diseases of pandemic potential. Key areas include systems approaches to drug delivery and targeting, development of long-acting and targeted therapeutics such as anti-retroviral therapies for HIV/AIDS, and studies on drug and lipid or biomaterial interactions to enhance drug potency and safety. He is recognized for his expertise in bio-therapeutics, lipid-drug interactions, liposomes, drug-combination nanoparticles, pharmacokinetics, and the interplay between tissue targets and drug penetration, leading to improved efficacy and safety of viral, cancer, and pain medications. Dr. Ho has served in leadership roles including Associate Dean for Research and New Initiatives, and he is actively involved in national and international initiatives related to cancer and HIV therapeutics. His contributions to pharmaceutical sciences and systems pharmacology have earned…
Research topics
- Chemistry
- Cancer research
- Pharmacology
- Biology
- Biophysics
- Biochemistry
- Medicine
- Internal medicine
- Materials science
- Biotechnology
Selected publications
Chemical Engineering Journal · 2020 · 158 citations
Pharmacology & Therapeutics · 2022 · 88 citations
Senior authorCorrespondingFood Chemistry · 2020 · 86 citations
U.S. patient preferences for long‐acting HIV treatment: a discrete choice experiment
Journal of the International AIDS Society · 2023-07-01 · 28 citations
articleOpen accessINTRODUCTION: Recent advances in long-acting antiretroviral therapy (LA-ART) could provide new options for HIV treatment and reduce adherence barriers, if regimens are acceptable to patients. We elicited preferences for key attributes of potential LA-ART regimens among people with HIV (PWH) in the United States, focusing on four treatment modes (oral tablets, subcutaneous injections, intramuscular injections, and implants), product characteristics and location of administration. METHODS: A discr…
Journal of Chromatography B · 2022-07-01 · 15 citations
article
Recent grants
NIH · $504k · 1996
NIH · $95.7M · 2012
NIH · $358k · 2009
Frequent coauthors
- 33 shared
Danny D. Shen
University of Washington
- 27 shared
Tot Bui
University of Washington
- 25 shared
Ann C. Collier
Duke University
- 21 shared
Jennifer Freeling
- 21 shared
Josefin Koehn
University of Washington
- 18 shared
John C. Kraft
University of Washington
- 17 shared
Jianguo Sun
China Pharmaceutical University
- 17 shared
Lisa A. McConnachie
Impel Neuropharma (United States)
Labs
Department of Pharmaceutics, School of Pharmacy, University of WashingtonPI
Education
Ph.D.
University of Tennessee
Other
University of California
Other
Stanford University
Awards & honors
- Paul Dawson Biotechnology life-time achievement award
- Volwiler life-time research achievement award
- AAPS Biotechnology Research achievement
Similar researchers at University of Washington
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Rodney JY Ho
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup
